Springhill Fund Asset Management HK Co Ltd Purchases New Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Springhill Fund Asset Management HK Co Ltd bought a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 29,600 shares of the company's stock, valued at approximately $1,585,000. Janux Therapeutics comprises 2.6% of Springhill Fund Asset Management HK Co Ltd's investment portfolio, making the stock its 15th largest holding. Springhill Fund Asset Management HK Co Ltd owned about 0.06% of Janux Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of JANX. Charles Schwab Investment Management Inc. lifted its stake in Janux Therapeutics by 202.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company's stock valued at $10,639,000 after buying an additional 156,675 shares in the last quarter. Lester Murray Antman dba SimplyRich lifted its position in shares of Janux Therapeutics by 205.3% in the 4th quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company's stock valued at $1,301,000 after acquiring an additional 16,351 shares in the last quarter. Geode Capital Management LLC grew its position in Janux Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company's stock worth $30,107,000 after purchasing an additional 38,490 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in shares of Janux Therapeutics in the third quarter valued at $940,000. Finally, abrdn plc acquired a new stake in shares of Janux Therapeutics in the fourth quarter worth $3,430,000. Institutional investors and hedge funds own 75.39% of the company's stock.

Remove Ads

Janux Therapeutics Stock Performance

Shares of NASDAQ JANX traded up $0.97 during mid-day trading on Friday, reaching $27.84. 544,321 shares of the company traded hands, compared to its average volume of 998,921. The company's fifty day moving average is $31.97 and its two-hundred day moving average is $44.29. Janux Therapeutics, Inc. has a fifty-two week low of $22.52 and a fifty-two week high of $71.71. The stock has a market cap of $1.65 billion, a PE ratio of -23.79 and a beta of 3.27.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Research analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on JANX shares. Lifesci Capital raised Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. HC Wainwright reissued a "buy" rating and issued a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Scotiabank decreased their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research note on Friday, February 28th. Finally, Wedbush restated an "outperform" rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $92.44.

Insider Activity

In related news, insider Andrew Hollman Meyer sold 3,334 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $32.15, for a total transaction of $107,188.10. Following the transaction, the insider now owns 82,139 shares of the company's stock, valued at approximately $2,640,768.85. The trade was a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. bought 110,206 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were bought at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the purchase, the director now owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. The trade was a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 29.40% of the stock is currently owned by company insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.